MovDisordV3, Main, Exploration, bibRecordById, pubmed:15027058

Basic immunological aspects of botulinum toxin therapy

Identifieur interne : 003E00 ( Main/Exploration ); précédent : 003D99; suivant : 003E01

Basic immunological aspects of botulinum toxin therapy

Auteurs : M. Zouhair Atassi [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2004-03.

RBID : ISTEX:24444F13DBEC4B3C4D9D5B76283A05E4E2F5DA20

English descriptors

KwdEn :
- Amino Acid Sequence, Animals, Antibodies (immunology), Botulinum Toxins (immunology), Botulinum Toxins (therapeutic use), Cross Reactions, Epitope Mapping, Humans, Immunization (methods), Immunotherapy, Neurotoxins (immunology), Neurotoxins (therapeutic use), Peptide Fragments (chemistry), Peptide Fragments (immunology), Tetanus Toxin (immunology), Time Factors, T‐cells, antibodies, botulinum neurotoxin, epitopes, immunoresistance, synthetic peptides, treatment.
MESH :
- chemical , chemistry : Peptide Fragments.
- chemical , immunology : Antibodies, Botulinum Toxins, Neurotoxins, Peptide Fragments, Tetanus Toxin.
- chemical , therapeutic use : Botulinum Toxins, Neurotoxins.
- methods : Immunization.
- Amino Acid Sequence, Animals, Cross Reactions, Epitope Mapping, Humans, Immunotherapy, Time Factors.

Abstract

Previous studies in this laboratory had mapped the immune recognition profile of the regions recognized antibodies (Abs) and by T cells on the protective HC domain (C‐terminal fragment corresponding to residues 855–1296 of the heavy chain) of botulinum neurotoxin serotype A (BoNT/A). The localization of these regions has several potential applications and has provided a basis for the understanding of immunoresistance to treatment. We briefly outline these localized regions and discuss the impact of these findings on the immunotherapeutic applications of BoNT/A. Immunoresistance to toxin therapy can appear in some patients after a few injections with the toxin. Our epitope mapping studies have shown that several factors can influence the immune response to the toxin. These factors include dose, duration of treatment, frequency of immunization, and quality of the toxin. The immune response to the whole toxin is under genetic control, and the response to each epitope is under separate genetic control. Therefore, the appearance of blocking Abs (i.e., immunoresistance) in patients might be controlled by the major histocompatability of the host. Once a patient becomes immunoresistant to one toxin then switching to another toxin will most often be of limited and short‐lived benefit, because the patient becomes rapidly immunoresistant to the second toxin. Finally, because of the considerable structural homology between tetanus neurotoxin (TeNT) and BoNTs, it is possible, although not certain, that a prior active immune response to TeNT might play some role in the early appearance on anti‐BoNT Abs in some patients. © 2004 Movement Disorder Society

Url:

https://api.istex.fr/document/24444F13DBEC4B3C4D9D5B76283A05E4E2F5DA20/fulltext/pdf

DOI: 10.1002/mds.20020

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Basic immunological aspects of botulinum toxin therapy</title>
<author><name sortKey="Atassi, M Zouhair" sort="Atassi, M Zouhair" uniqKey="Atassi M" first="M. Zouhair" last="Atassi">M. Zouhair Atassi</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:24444F13DBEC4B3C4D9D5B76283A05E4E2F5DA20</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.20020</idno>
<idno type="url">https://api.istex.fr/document/24444F13DBEC4B3C4D9D5B76283A05E4E2F5DA20/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000154</idno>
<idno type="wicri:Area/Istex/Curation">000154</idno>
<idno type="wicri:Area/Istex/Checkpoint">002781</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Atassi M:basic:immunological:aspects</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15027058</idno>
<idno type="wicri:Area/PubMed/Corpus">003509</idno>
<idno type="wicri:Area/PubMed/Curation">003509</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003548</idno>
<idno type="wicri:Area/Ncbi/Merge">000D75</idno>
<idno type="wicri:Area/Ncbi/Curation">000D75</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000D75</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Atassi M:basic:immunological:aspects</idno>
<idno type="wicri:Area/Main/Merge">005758</idno>
<idno type="wicri:Area/Main/Curation">003E00</idno>
<idno type="wicri:Area/Main/Exploration">003E00</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Basic immunological aspects of botulinum toxin therapy</title>
<author><name sortKey="Atassi, M Zouhair" sort="Atassi, M Zouhair" uniqKey="Atassi M" first="M. Zouhair" last="Atassi">M. Zouhair Atassi</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biochemistry and Molecular Biology, and Department of Immunology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-03">2004-03</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">S8</biblScope>
<biblScope unit="page" from="S68">S68</biblScope>
<biblScope unit="page" to="S84">S84</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">24444F13DBEC4B3C4D9D5B76283A05E4E2F5DA20</idno>
<idno type="DOI">10.1002/mds.20020</idno>
<idno type="ArticleID">MDS20020</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Antibodies (immunology)</term>
<term>Botulinum Toxins (immunology)</term>
<term>Botulinum Toxins (therapeutic use)</term>
<term>Cross Reactions</term>
<term>Epitope Mapping</term>
<term>Humans</term>
<term>Immunization (methods)</term>
<term>Immunotherapy</term>
<term>Neurotoxins (immunology)</term>
<term>Neurotoxins (therapeutic use)</term>
<term>Peptide Fragments (chemistry)</term>
<term>Peptide Fragments (immunology)</term>
<term>Tetanus Toxin (immunology)</term>
<term>Time Factors</term>
<term>T‐cells</term>
<term>antibodies</term>
<term>botulinum neurotoxin</term>
<term>epitopes</term>
<term>immunoresistance</term>
<term>synthetic peptides</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Peptide Fragments</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies</term>
<term>Botulinum Toxins</term>
<term>Neurotoxins</term>
<term>Peptide Fragments</term>
<term>Tetanus Toxin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins</term>
<term>Neurotoxins</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Cross Reactions</term>
<term>Epitope Mapping</term>
<term>Humans</term>
<term>Immunotherapy</term>
<term>Time Factors</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Previous studies in this laboratory had mapped the immune recognition profile of the regions recognized antibodies (Abs) and by T cells on the protective HC domain (C‐terminal fragment corresponding to residues 855–1296 of the heavy chain) of botulinum neurotoxin serotype A (BoNT/A). The localization of these regions has several potential applications and has provided a basis for the understanding of immunoresistance to treatment. We briefly outline these localized regions and discuss the impact of these findings on the immunotherapeutic applications of BoNT/A. Immunoresistance to toxin therapy can appear in some patients after a few injections with the toxin. Our epitope mapping studies have shown that several factors can influence the immune response to the toxin. These factors include dose, duration of treatment, frequency of immunization, and quality of the toxin. The immune response to the whole toxin is under genetic control, and the response to each epitope is under separate genetic control. Therefore, the appearance of blocking Abs (i.e., immunoresistance) in patients might be controlled by the major histocompatability of the host. Once a patient becomes immunoresistant to one toxin then switching to another toxin will most often be of limited and short‐lived benefit, because the patient becomes rapidly immunoresistant to the second toxin. Finally, because of the considerable structural homology between tetanus neurotoxin (TeNT) and BoNTs, it is possible, although not certain, that a prior active immune response to TeNT might play some role in the early appearance on anti‐BoNT Abs in some patients. © 2004 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Texas</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Atassi, M Zouhair" sort="Atassi, M Zouhair" uniqKey="Atassi M" first="M. Zouhair" last="Atassi">M. Zouhair Atassi</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E00 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003E00 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:24444F13DBEC4B3C4D9D5B76283A05E4E2F5DA20
   |texte=   Basic immunological aspects of botulinum toxin therapy
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Basic immunological aspects of botulinum toxin therapy

Basic immunological aspects of botulinum toxin therapy

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.